---
schema_version: "secwatch.filing_event.v1"
accession: "0001821586-24-000028"
form_type: "8-K"
ticker: "MLTX"
cik: "0001821586"
company_name: "MoonLake Immunotherapeutics"
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:46:51.769874+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# MoonLake Q3 cash $493.9M; Phase 3 HS readout on track for mid-2025

## Summary
- Cash, equivalents and short-term debt securities of $493.9M as of Sep 30; runway to end of 2026.
- R&D expenses of $35.7M in Q3, up from $23.7M prior quarter, driven by Phase 3 HS ramp-up.
- Phase 3 VELA program in HS actively enrolling; primary endpoint readout anticipated as of mid-2025.
- Phase 3 PsA program (IZAR-1 and IZAR-2) enrollment expected to commence imminently.
- Additional Phase 2 trials in PPP, axSpA, and Phase 3 adolescent HS to start around year-end 2024.

## SEC filing metadata
- accession: 0001821586-24-000028
- form_type: 8-K
- ticker: MLTX
- cik: 0001821586
- company_name: MoonLake Immunotherapeutics
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1821586/000182158624000028/0001821586-24-000028-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1821586/000182158624000028/mnlk-20241107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001821586-24-000028
- JSON: https://secwatch.observer/filing/0001821586-24-000028.json
- Plain text: https://secwatch.observer/filing/0001821586-24-000028.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.